JP2014513694A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014513694A5 JP2014513694A5 JP2014510427A JP2014510427A JP2014513694A5 JP 2014513694 A5 JP2014513694 A5 JP 2014513694A5 JP 2014510427 A JP2014510427 A JP 2014510427A JP 2014510427 A JP2014510427 A JP 2014510427A JP 2014513694 A5 JP2014513694 A5 JP 2014513694A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- inhibitor
- administered
- dose
- amyloid plaques
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037259 Amyloid Plaque Diseases 0.000 claims description 12
- VEPKQEUBKLEPRA-UHFFFAOYSA-N VX-745 Chemical group FC1=CC(F)=CC=C1SC1=NN2C=NC(=O)C(C=3C(=CC=CC=3Cl)Cl)=C2C=C1 VEPKQEUBKLEPRA-UHFFFAOYSA-N 0.000 claims description 9
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims description 7
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims description 7
- 210000004556 brain Anatomy 0.000 claims description 4
- 102000043136 MAP kinase family Human genes 0.000 claims 2
- 108091054455 MAP kinase family Proteins 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 238000000034 method Methods 0.000 description 33
- 239000012826 P38 inhibitor Substances 0.000 description 13
- 229940126560 MAPK inhibitor Drugs 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 5
- -1 SB 200025 Chemical compound 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 238000002610 neuroimaging Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- FWZRHQBGQFAXCP-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-(4-methylphenyl)urea Chemical compound C1=CC(C)=CC=C1NC(=O)NC1=CC(C(C)(C)C)=NN1C1=CC=C(C)C=C1 FWZRHQBGQFAXCP-UHFFFAOYSA-N 0.000 description 1
- NVXXMMXIJGUQGI-UHFFFAOYSA-N 2-(4-fluorophenyl)-6-methoxy-3-pyridin-4-yl-1h-indole Chemical compound N1C2=CC(OC)=CC=C2C(C=2C=CN=CC=2)=C1C1=CC=C(F)C=C1 NVXXMMXIJGUQGI-UHFFFAOYSA-N 0.000 description 1
- ZQAQXZBSGZUUNL-BJUDXGSMSA-N 2-[4-(methylamino)phenyl]-1,3-benzothiazol-6-ol Chemical compound C1=CC(N[11CH3])=CC=C1C1=NC2=CC=C(O)C=C2S1 ZQAQXZBSGZUUNL-BJUDXGSMSA-N 0.000 description 1
- GUTYHDCSDBBMGW-UHFFFAOYSA-N 2-[6-chloro-5-[4-[(4-fluorophenyl)methyl]piperidine-1-carbonyl]-1-methylindol-3-yl]-n,n-dimethyl-2-oxoacetamide Chemical compound C1=C2C(C(=O)C(=O)N(C)C)=CN(C)C2=CC(Cl)=C1C(=O)N(CC1)CCC1CC1=CC=C(F)C=C1 GUTYHDCSDBBMGW-UHFFFAOYSA-N 0.000 description 1
- DPGNJQAIOXNWEY-UHFFFAOYSA-N 3-(4-fluorophenyl)-2-pyridin-4-yl-1h-pyrrolo[3,2-b]pyridine Chemical compound C1=CC(F)=CC=C1C1=C(C=2C=CN=CC=2)NC2=CC=CN=C12 DPGNJQAIOXNWEY-UHFFFAOYSA-N 0.000 description 1
- VMAKTIDYMSNPOV-UHFFFAOYSA-N 4,6-bis(4-fluorophenyl)-2-methyl-5-pyridin-4-ylpyrazolo[3,4-b]pyridine Chemical compound C=1C=NC=CC=1C=1C(C=2C=CC(F)=CC=2)=NC2=NN(C)C=C2C=1C1=CC=C(F)C=C1 VMAKTIDYMSNPOV-UHFFFAOYSA-N 0.000 description 1
- KHPOPEMUEPWTJQ-UHFFFAOYSA-N 4-(4-fluorophenyl)-5-(3-propan-2-ylbenzotriazol-5-yl)-1,3-oxazole Chemical compound C1=C2N(C(C)C)N=NC2=CC=C1C=1OC=NC=1C1=CC=C(F)C=C1 KHPOPEMUEPWTJQ-UHFFFAOYSA-N 0.000 description 1
- ODYAQBDIXCVKAE-UHFFFAOYSA-N 4-[4-(2-fluorophenyl)phenyl]-N-(4-hydroxyphenyl)butanamide Chemical compound C1=CC(O)=CC=C1NC(=O)CCCC1=CC=C(C=2C(=CC=CC=2)F)C=C1 ODYAQBDIXCVKAE-UHFFFAOYSA-N 0.000 description 1
- QSUSKMBNZQHHPA-UHFFFAOYSA-N 4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-pyridin-4-ylimidazol-2-yl]but-3-yn-1-ol Chemical compound C=1C=CC=CC=1CCCN1C(C#CCCO)=NC(C=2C=CC(F)=CC=2)=C1C1=CC=NC=C1 QSUSKMBNZQHHPA-UHFFFAOYSA-N 0.000 description 1
- BGIYKDUASORTBB-UHFFFAOYSA-N 4-[4-(4-fluorophenyl)-2-(4-nitrophenyl)-1H-imidazol-5-yl]pyridine Chemical compound C1=CC([N+](=O)[O-])=CC=C1C1=NC(C=2C=CC(F)=CC=2)=C(C=2C=CN=CC=2)N1 BGIYKDUASORTBB-UHFFFAOYSA-N 0.000 description 1
- PDTYLGXVBIWRIM-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)-3-piperidin-4-ylimidazol-4-yl]-2-methoxypyrimidine Chemical compound COC1=NC=CC(C=2N(C=NC=2C=2C=CC(F)=CC=2)C2CCNCC2)=N1 PDTYLGXVBIWRIM-UHFFFAOYSA-N 0.000 description 1
- GVNFHOOLMZHSSF-BJLQDIEVSA-N 6-(1,4-diazepan-1-yl)-4-N-[[(1S,2R,5S)-6,6-dimethyl-2-bicyclo[3.1.1]heptanyl]methyl]-2-N-phenyl-1,3,5-triazine-2,4-diamine Chemical compound N1(CCNCCC1)C1=NC(=NC(=N1)NC[C@H]1[C@H]2C([C@@H](CC1)C2)(C)C)NC1=CC=CC=C1 GVNFHOOLMZHSSF-BJLQDIEVSA-N 0.000 description 1
- YOELZIQOLWZLQC-UHFFFAOYSA-N 6-(4-fluorophenyl)-5-pyridin-4-yl-2,3-dihydroimidazo[2,1-b]thiazole Chemical compound C1=CC(F)=CC=C1C1=C(C=2C=CN=CC=2)N2CCSC2=N1 YOELZIQOLWZLQC-UHFFFAOYSA-N 0.000 description 1
- FYSRKRZDBHOFAY-UHFFFAOYSA-N 6-(N-carbamoyl-2,6-difluoroanilino)-2-(2,4-difluorophenyl)-3-pyridinecarboxamide Chemical group FC=1C=CC=C(F)C=1N(C(=O)N)C(N=1)=CC=C(C(N)=O)C=1C1=CC=C(F)C=C1F FYSRKRZDBHOFAY-UHFFFAOYSA-N 0.000 description 1
- NQPPPAJKEZYMMP-UHFFFAOYSA-N 6-[2-(2,6-difluorophenyl)-5-phenyl-1h-imidazol-4-yl]-1-propan-2-ylsulfonylbenzimidazol-2-amine Chemical compound C1=C2N(S(=O)(=O)C(C)C)C(N)=NC2=CC=C1C=1N=C(C=2C(=CC=CC=2F)F)NC=1C1=CC=CC=C1 NQPPPAJKEZYMMP-UHFFFAOYSA-N 0.000 description 1
- ORVNHOYNEHYKJG-UHFFFAOYSA-N 8-(2,6-difluorophenyl)-2-(1,3-dihydroxypropan-2-ylamino)-4-(4-fluoro-2-methylphenyl)pyrido[2,3-d]pyrimidin-7-one Chemical compound CC1=CC(F)=CC=C1C1=NC(NC(CO)CO)=NC2=C1C=CC(=O)N2C1=C(F)C=CC=C1F ORVNHOYNEHYKJG-UHFFFAOYSA-N 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- SUFIGNYZARZDJD-UHFFFAOYSA-N ClC1=C(C(=CC=C1)Cl)C=1C(N=CN2N=C(C=CC21)SC2=C(C=C(C=C2)F)F)=O.C=O Chemical compound ClC1=C(C(=CC=C1)Cl)C=1C(N=CN2N=C(C=CC21)SC2=C(C=C(C=C2)F)F)=O.C=O SUFIGNYZARZDJD-UHFFFAOYSA-N 0.000 description 1
- 101000711846 Homo sapiens Transcription factor SOX-9 Proteins 0.000 description 1
- HEKAIDKUDLCBRU-UHFFFAOYSA-N N-[4-[2-ethyl-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]benzamide Chemical compound S1C(CC)=NC(C=2C=C(C)C=CC=2)=C1C(C=1)=CC=NC=1NC(=O)C1=CC=CC=C1 HEKAIDKUDLCBRU-UHFFFAOYSA-N 0.000 description 1
- CDMGBJANTYXAIV-UHFFFAOYSA-N SB 203580 Chemical compound C1=CC(S(=O)C)=CC=C1C1=NC(C=2C=CC(F)=CC=2)=C(C=2C=CN=CC=2)N1 CDMGBJANTYXAIV-UHFFFAOYSA-N 0.000 description 1
- 102100034204 Transcription factor SOX-9 Human genes 0.000 description 1
- RERSCSYZEKLVHG-UHFFFAOYSA-N [2-[5-[2-(cyclopropylamino)pyrimidin-4-yl]-4-(4-fluorophenyl)-1h-imidazol-2-yl]-5-methyl-1,3-dioxan-5-yl]-morpholin-4-ylmethanone Chemical compound O1CC(C)(C(=O)N2CCOCC2)COC1C(N1)=NC(C=2C=CC(F)=CC=2)=C1C(N=1)=CC=NC=1NC1CC1 RERSCSYZEKLVHG-UHFFFAOYSA-N 0.000 description 1
- OMGLGPKQUFSRNN-UHFFFAOYSA-N [2-methoxy-4-(methylthio)phenyl]-[4-(phenylmethyl)-1-piperidinyl]methanone Chemical compound COC1=CC(SC)=CC=C1C(=O)N1CCC(CC=2C=CC=CC=2)CC1 OMGLGPKQUFSRNN-UHFFFAOYSA-N 0.000 description 1
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 description 1
- 229940011658 asiatic acid Drugs 0.000 description 1
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- HYXPWOSDWIYCSH-QRIJWHNFSA-N chembl308003 Chemical compound CS(O)(=O)=O.N1C([C@H]2OC[C@](CO2)(C)C(=O)N2CCOCC2)=NC(C=2C=CC(F)=CC=2)=C1C1=CC=NC=C1 HYXPWOSDWIYCSH-QRIJWHNFSA-N 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- MVCOAUNKQVWQHZ-UHFFFAOYSA-N doramapimod Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 MVCOAUNKQVWQHZ-UHFFFAOYSA-N 0.000 description 1
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 description 1
- YNDIAUKFXKEXSV-CRYLGTRXSA-N florbetapir F-18 Chemical compound C1=CC(NC)=CC=C1\C=C\C1=CC=C(OCCOCCOCC[18F])N=C1 YNDIAUKFXKEXSV-CRYLGTRXSA-N 0.000 description 1
- 229960005373 florbetapir f-18 Drugs 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- ZXONHXQWZPBOLO-GOSISDBHSA-N n-[(1r)-1-phenylethyl]-4-[6-piperidin-4-yl-3-[3-(trifluoromethyl)phenyl]pyridazin-4-yl]pyrimidin-2-amine Chemical compound N([C@H](C)C=1C=CC=CC=1)C(N=1)=NC=CC=1C1=CC(C2CCNCC2)=NN=C1C1=CC=CC(C(F)(F)F)=C1 ZXONHXQWZPBOLO-GOSISDBHSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 230000005311 nuclear magnetism Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- ZMELOYOKMZBMRB-DLBZAZTESA-N talmapimod Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)C=2C(=CC=3N(C)C=C(C=3C=2)C(=O)C(=O)N(C)C)Cl)N1CC1=CC=C(F)C=C1 ZMELOYOKMZBMRB-DLBZAZTESA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161483919P | 2011-05-09 | 2011-05-09 | |
| US61/483,919 | 2011-05-09 | ||
| PCT/US2012/037064 WO2012154814A1 (en) | 2011-05-09 | 2012-05-09 | Compositions and methods for treating alzheimer's disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015186148A Division JP6114355B2 (ja) | 2011-05-09 | 2015-09-22 | アルツハイマー病を処置するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014513694A JP2014513694A (ja) | 2014-06-05 |
| JP2014513694A5 true JP2014513694A5 (enExample) | 2015-06-25 |
| JP5851022B2 JP5851022B2 (ja) | 2016-02-03 |
Family
ID=47139618
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014510427A Expired - Fee Related JP5851022B2 (ja) | 2011-05-09 | 2012-05-09 | アルツハイマー病を処置するための組成物および方法 |
| JP2015186148A Active JP6114355B2 (ja) | 2011-05-09 | 2015-09-22 | アルツハイマー病を処置するための組成物および方法 |
| JP2017019250A Withdrawn JP2017075191A (ja) | 2011-05-09 | 2017-02-06 | アルツハイマー病を処置するための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015186148A Active JP6114355B2 (ja) | 2011-05-09 | 2015-09-22 | アルツハイマー病を処置するための組成物および方法 |
| JP2017019250A Withdrawn JP2017075191A (ja) | 2011-05-09 | 2017-02-06 | アルツハイマー病を処置するための組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US8697627B2 (enExample) |
| EP (2) | EP3081568B1 (enExample) |
| JP (3) | JP5851022B2 (enExample) |
| CN (1) | CN103842362B (enExample) |
| AU (1) | AU2012253615B2 (enExample) |
| CA (1) | CA2835707C (enExample) |
| DK (1) | DK3081568T3 (enExample) |
| ES (1) | ES2773480T3 (enExample) |
| WO (1) | WO2012154814A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2651405A2 (en) | 2010-12-14 | 2013-10-23 | Electrophoretics Limited | Casein kinase 1 (ck1 ) inhibitors |
| CA2835707C (en) | 2011-05-09 | 2019-02-26 | Eip Pharma, Llc | Compositions and methods for treating alzheimer's disease |
| US20150104870A1 (en) * | 2012-04-27 | 2015-04-16 | Keio University | Neuronal differentiation promoter |
| EP2968322B1 (en) | 2013-03-15 | 2018-12-26 | The Trustees of Columbia University in the City of New York | Map kinase modulators and uses thereof |
| GB201319620D0 (en) * | 2013-11-06 | 2013-12-18 | Norwegian University Of Science And Technology | Immunosuppressive agents and their use in therapy |
| JP6163084B2 (ja) * | 2013-11-11 | 2017-07-12 | キリン株式会社 | 認知症の予防、治療及び／又は認知機能を改善する組成物、及びこれを用いた医薬、食品 |
| US9579322B2 (en) * | 2014-07-09 | 2017-02-28 | Eip Pharma, Llc | Methods for treating neurologic disorders |
| EP3172211B1 (en) | 2014-07-22 | 2019-07-03 | GlaxoSmithKline Intellectual Property Development Limited | Tricyclic imidazo-pyrimidinone derivatives for the treatment of diseases mediated by lp-pla2 |
| JP2016193870A (ja) * | 2015-04-01 | 2016-11-17 | 国立大学法人広島大学 | 慢性骨髄性白血病治療剤 |
| EP3325992B1 (en) | 2015-07-24 | 2026-01-28 | Northeastern University | Quantitative magnetic resonance imaging of the vasculature |
| WO2017185073A1 (en) * | 2016-04-21 | 2017-10-26 | Eip Pharma, Llc | Compositions and methods for treating dementia |
| MX375277B (es) * | 2016-06-03 | 2025-03-06 | Univ Columbia | Métodos para tratar el síndrome de prader-willi |
| GB201611712D0 (en) | 2016-07-02 | 2016-08-17 | Hvivo Services Ltd | Methods and compounds for the treatment or prevention of severe or persistent influenza |
| US11466008B2 (en) | 2017-09-18 | 2022-10-11 | Eip Pharma, Llc | Co-crystals of neflamapimod (VX-745) |
| MX2020004005A (es) | 2017-10-03 | 2020-10-05 | Prevail Therapeutics Inc | Terapias genicas para los trastornos lisosomales. |
| EP3692158A4 (en) | 2017-10-03 | 2021-08-04 | Prevail Therapeutics, Inc. | GENE THERAPIES FOR LYSOSOMAL DISEASES |
| ES2927715T3 (es) | 2017-10-05 | 2022-11-10 | Fulcrum Therapeutics Inc | Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD |
| GB201721793D0 (en) | 2017-12-22 | 2018-02-07 | Hvivo Services Ltd | Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza |
| CA3125548A1 (en) | 2019-01-03 | 2020-07-09 | Northeastern University | Quantitative measurement of disruptions in the blood brain barrier |
| US12642433B2 (en) | 2019-01-25 | 2026-06-02 | Northeastern University | Quantitative measurement of the perivascular space for CNS and brain disorders |
| CN111789949A (zh) * | 2019-04-08 | 2020-10-20 | 北京昱嘉科技集团有限公司 | 基于特异性趋化因子受体的阿尔兹海默病治疗靶点 |
| JP7664848B2 (ja) | 2019-04-10 | 2025-04-18 | プリベイル セラピューティクス，インコーポレーテッド | リソソーム障害のための遺伝子療法 |
| WO2021216754A1 (en) * | 2020-04-21 | 2021-10-28 | Spring Discovery, Inc. | Use of p38 mapk inhibitors for prevention and treatment of aging and aging-related disorders and for boosting an immune system |
| US20230010690A1 (en) * | 2021-07-08 | 2023-01-12 | Morehouse School Of Medicine | Method and system of diagnosing and treating neurodegenerative disease and seizures |
| WO2023282900A1 (en) * | 2021-07-08 | 2023-01-12 | Morehouse School Of Medicine | Method and system of diagnosing and treating neurodegenerative disease and seizures |
| WO2023004054A1 (en) * | 2021-07-23 | 2023-01-26 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for the treatment of alzheimer's disease |
| EP4252748A1 (en) * | 2022-03-31 | 2023-10-04 | Otto-von-Guericke-University Magdeburg | A sphingosine-1-phosphate receptor (s1pr) modulator for use in treating a patient suffering from alzheimer's dementia |
| EP4342394A1 (de) | 2022-09-23 | 2024-03-27 | MTS Medical UG | Vorrichtung und system zur behandlung von alzheimererkrankungen |
| CN115887641B (zh) * | 2022-11-23 | 2024-06-21 | 四川大学华西医院 | 他米巴罗汀在制备免疫佐剂中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6147080A (en) * | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| US20050203111A1 (en) * | 2004-03-12 | 2005-09-15 | Vvii Newco 2003, Inc. | Compositions and methods for preventing and treating skin and hair conditions |
| US20080044439A1 (en) | 2004-03-11 | 2008-02-21 | David Nathaniel E | Compositions and Methods for Preventing and Treating Skin and Hair Conditions |
| WO2008002465A2 (en) * | 2006-06-23 | 2008-01-03 | The Feinstein Institute For Medical Research | INHIBITORS OF Aβ AND SYNUCLEIN AGGREGATION |
| CA2835707C (en) | 2011-05-09 | 2019-02-26 | Eip Pharma, Llc | Compositions and methods for treating alzheimer's disease |
-
2012
- 2012-05-09 CA CA2835707A patent/CA2835707C/en active Active
- 2012-05-09 US US13/467,519 patent/US8697627B2/en active Active
- 2012-05-09 EP EP16169411.2A patent/EP3081568B1/en active Active
- 2012-05-09 WO PCT/US2012/037064 patent/WO2012154814A1/en not_active Ceased
- 2012-05-09 JP JP2014510427A patent/JP5851022B2/ja not_active Expired - Fee Related
- 2012-05-09 ES ES16169411T patent/ES2773480T3/es active Active
- 2012-05-09 CN CN201280034096.2A patent/CN103842362B/zh active Active
- 2012-05-09 EP EP12782660.0A patent/EP2707369B1/en not_active Not-in-force
- 2012-05-09 AU AU2012253615A patent/AU2012253615B2/en active Active
- 2012-05-09 DK DK16169411.2T patent/DK3081568T3/da active
-
2014
- 2014-02-27 US US14/191,984 patent/US20140357638A1/en not_active Abandoned
-
2015
- 2015-09-15 US US14/855,338 patent/US9427438B2/en active Active
- 2015-09-22 JP JP2015186148A patent/JP6114355B2/ja active Active
-
2017
- 2017-02-06 JP JP2017019250A patent/JP2017075191A/ja not_active Withdrawn